【摘要】：【目的】探討SPAG5對卵巢高級別漿液性癌細(xì)胞生長及紫杉醇藥物敏感性的影響,分析原發(fā)灶組織中表達(dá)水平差異與患者預(yù)后關(guān)系�！痉椒ā矿w外實(shí)驗(yàn)中通過瞬時敲降卵巢腺癌細(xì)胞株中SPAG5,紫杉醇處理細(xì)胞后,MTT法檢測細(xì)胞活力及繪制細(xì)胞生長曲線,研究SPAG5對細(xì)胞生長增殖及紫醇敏感性的影響;然后通過免疫組織化學(xué)染色,研究110例患者組織中SPAG5表達(dá)水平與患者預(yù)后的關(guān)系�！窘Y(jié)果】SKOV3細(xì)胞中敲降SPAG5后發(fā)生細(xì)胞周期G2/M期阻滯,使細(xì)胞生長明顯受抑;免疫組織化學(xué)染色顯示,12例接受新輔助化療患者腫瘤組織中SPGA5表達(dá)明顯升高,對于未接受新輔助化療患者,SPAG5低表達(dá)者疾病無進(jìn)展生存較差,早期患者中差異更顯著,患者總生存也有相似趨勢,但差異無統(tǒng)計(jì)學(xué)意義;在卵巢腺癌細(xì)胞株OVCAR3 A2780及SKOV3中敲降SPAG5后,細(xì)胞對0.5μmol/L紫杉醇抵抗能力增強(qiáng)�！窘Y(jié)論】SPAG5在卵巢腺癌細(xì)胞中調(diào)控細(xì)胞周期,促進(jìn)細(xì)胞增殖,但早期卵巢高級別漿液性癌患者中SPAG5低表達(dá)者對紫杉醇的藥物作用敏感性差,相應(yīng)預(yù)后差,因此卵巢高級別漿液性癌輔助化療方案應(yīng)個體化選擇。
[Abstract]:[objective] to investigate the effects of SPAG5 on the growth of ovarian high-grade serous cancer cells and the drug sensitivity of paclitaxel. To analyze the relationship between the expression level of primary tumor tissue and the prognosis of the patients. [methods] in vitro, SPAG5, paclitaxel was used to treat the ovarian adenocarcinoma cell line, and the cell viability and cell growth curve were measured by MTT method. To study the effect of SPAG5 on cell proliferation and the sensitivity of Violol, and then by immunohistochemical staining, To study the relationship between the expression level of SPAG5 and the prognosis of the patients. [results] after knocking down SPAG5 in SKOV3 cells, cell cycle G _ 2 / M phase arrest occurred and cell growth was significantly inhibited. Immunohistochemical staining showed that the expression of SPGA5 was significantly increased in tumor tissues of 12 patients with neoadjuvant chemotherapy. For patients without neoadjuvant chemotherapy, patients with low expression of SPAG5 had no progressive survival, and the difference was more significant in early patients. The total survival of the patients was similar, but the difference was not statistically significant. After knocking down SPAG5 in the ovarian adenocarcinoma cell line OVCAR3 A2780 and SKOV3, the resistance of the cells to 0.5 渭 mol/L paclitaxel was enhanced. [conclusion] SPAG5 regulates cell cycle in ovarian adenocarcinoma cells. Promote cell proliferation, but the low expression of SPAG5 in early ovarian high-grade serous carcinoma patients have poor sensitivity to paclitaxel and poor prognosis. Therefore, adjuvant chemotherapy regimen for ovarian high-grade serous carcinoma should be individualized.
【作者單位】： 中山大學(xué)附屬第一醫(yī)院婦產(chǎn)科;中山大學(xué)腫瘤防治中心婦科;
【基金】：廣東省自然科學(xué)基金(2016A030310171)
【分類號】：R737.31

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王波,張貴宇;卵巢外腹膜乳頭狀漿液性癌[J];國外醫(yī)學(xué).婦產(chǎn)科學(xué)分冊;1995年02期

2 王蘇榮,王波,李曉明;卵巢微乳頭型漿液性癌的研究進(jìn)展[J];中華婦產(chǎn)科雜志;2005年08期

3 孫e，

本文編號：2278904